Orforglipron has not yet received FDA approval. The drug, developed by Eli Lilly and Company, is an oral small molecule for the treatment of obesity. It is currently undergoing Phase 3 clinical trials. [1]
What is the status of Orforglipron's clinical trials?
Orforglipron is in Phase 3 clinical development for obesity. Eli Lilly announced in January 2024 that the first patient had been enrolled in a Phase 3 trial for the drug. The company anticipates that these trials will conclude in 2025, with a potential submission for regulatory approval in the United States to follow. [1]
When might Orforglipron be approved?
Based on the ongoing Phase 3 trials, which are expected to conclude in 2025, regulatory submission in the U.S. could occur after that. This suggests that FDA approval would likely not be before 2026, assuming successful trial outcomes and a smooth regulatory review process. [1]
How does Orforglipron work?
Orforglipron is a nonpeptide oral agonist of the glucagon-like peptide-1 (GLP-1) receptor. Unlike injectable GLP-1 receptor agonists, it is taken by mouth as a pill. [1]
What are the known side effects of Orforglipron?
In Phase 2 studies, the most common side effects reported were gastrointestinal issues, such as nausea, vomiting, diarrhea, and abdominal pain. The severity and frequency of these side effects varied depending on the dosage. [1]
How does Orforglipron compare to other weight-loss medications?
Orforglipron aims to offer an oral alternative to existing injectable GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound). Its oral administration could be a significant advantage for patient convenience. [1]
What is the patent situation for Orforglipron?
Information regarding specific patent expiry dates for Orforglipron is not publicly available at this stage of its development. Drug patent information can be tracked through resources like DrugPatentWatch.com. [2]
Sources:
[1] Eli Lilly and Company
[2] DrugPatentWatch.com